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The fi rst confi rmed cases of coronavirus disease (COVID-19) in the United Kingdom were iden-
tifi ed at the end of January 2020. As cases increased 
across all regions, surveillance data indicated that the 
epidemic was progressing more rapidly in London 
than the rest of the United Kingdom. In response to 
the increase in cases, hospitalizations, and deaths, the 
United Kingdom introduced a series of measures to 
limit transmission, beginning March 12, 2020 (week 
11); persons with a continuous cough or fever were 
advised to self-isolate for 7 days, school trips abroad 
were cancelled, and at-risk groups were advised to 
avoid cruises. These measures culminated in the im-
plementation of legally enforceable public health and 
social measures (i.e., lockdown) beginning March 23 
(week 13) (1).
Despite the reporting of a range of surveillance 
data in England, including laboratory-confi rmed 
cases, primary-care consultations, hospital and inten-
sive care unit (ICU) admissions, and deaths (2), much 
remains unknown about the magnitude of infection 
with severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2) virus in the population, the key driv-
ers of transmission, and the incidence of asymptom-
atic or mildly symptomatic infection within the UK 
population thus far.
Serologic estimates are critical to better under-
stand epidemiologic trends and help inform policy 
options to control disease. These estimates also pro-
vide a denominator for estimating severity measures, 
such as infection fatality and infection hospitalization 
ratios, and to help clarify the epidemiology of COV-
ID-19 in the population.
Early in the pandemic, data from population-
based seroepidemiologic studies were limited (N. 
Bobrovitz et al., unpub. data, https://doi.org/10.1
101/2020.05.10.20097451), and how the prevalence 
of SARS-CoV-2 infection varies by age was not well 
understood. Much remains unknown about the dy-
namics of the antibody response to SARS-CoV-2. 
The existing serologic assays target different viral 
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We	describe	 results	 of	 testing	 blood	 donors	 in	 London,	
UK,	 for	 severe	 acute	 respiratory	 disease	 coronavirus	 2	
(SARS-CoV-2)	IgG	before	and	after	lockdown	measures.	
Anonymized	 samples	 from	 donors	 17–69	 years	 of	 age	
were	tested	using	3	assays:	Euroimmun	IgG,	Abbott	IgG,	
and	 an	 immunoglobulin	 receptor-binding	 domain	 assay	
developed	 by	 Public	 Health	 England.	 Seroprevalence	
increased	 from	 3.0%	 prelockdown	 (week	 13,	 beginning	
March	23,	2020)	 to	10.4%	during	 lockdown	(weeks	15–
16)	 and	 12.3%	 postlockdown	 (week	 18)	 by	 the	Abbott	
assay.	 Estimates	were	 2.9%	 prelockdown,	 9.9%	 during	
lockdown,	 and	 13.0%	 postlockdown	 by	 the	 Euroimmun	










proteins, and IgG responses to these proteins are 
likely to appear at different stages of the immune 
response, potentially resulting in some assays pref-
erentially identifying those persons seroconverting 
earlier or later in the course of an infection (3); these 
differences are an important factor when interpret-
ing data from seroprevalence studies. In this article, 
we describe the results of testing whole blood do-
nors in London, UK, who were anonymously tested 
as part of the national public health response to CO-
VID-19. These tests were conducted using 3 different 
serologic assays at 3 timepoints during the epidemic 
that reflect transmission prelockdown, perilock-




A program of collecting plasma samples each week 
through the National Health Service Blood and 
Transplant Services from healthy 17–69 year old per-
sons donating whole blood was initiated on March 
23, 2020, at epidemiologic week 13. The minimum in-
terval between serial donations was 12 weeks for men 
and 16 weeks for women. An average of 10,683 whole 
blood donations were received per month in London 
during March–July 2020.
Given the evidence of the scale of the epidemic 
in London, enhanced testing of London donors was 
implemented with donor samples from London col-
lected during week 13 (period 1, beginning March 
23), weeks 15–16 (period 2), and week 18 (period 3). 
Approximately 1,000 fully anonymized donations 
were obtained for each collection. The demographic 
information available from each donor included age, 
sex, and area of residence.
Blood donors are healthy persons who are ex-
cluded from donating if they experienced any acute 
illness for >2 weeks before donating blood. In addi-
tion, specific donor exclusion criteria for coronavirus 
have been introduced (14 days postinfection at the 
time of the study, which was extended to 28 days 
starting June 8) (4). Given the standard symptomatic 
period, the exclusion criteria described and the fact 
that antibodies might take >2 weeks to be detectable, 
prevalence estimates among blood donors probably 
reflect infection prevalence >2–4 weeks before sam-
ples were taken.
To undertake the validation of test sensitivity, 
samples from recovering case-patients are required. 
To obtain convalescent serum samples from case- 
patients in the community, Public Health England 
(PHE) initiated an active request for samples from per-
sons with PCR-confirmed cases reported early in the 
epidemic. These persons were asked to attend their 
general practitioner approximately 3–5 weeks after 
illness onset to provide a convalescent serum sample 
(N.L. Boddington et al., unpub. data, https://doi.org
/10.1101/2020.05.18.20086157). Crucially, these cases 
were detected in the containment phase, when test-
ing was based on epidemiologic factors such as trav-
el. These cases should therefore be a better reflection 
of mild and asymptomatic infections that would not 
otherwise be picked up by routine testing, which was 
based predominantly on testing hospitalized patients 
at the 3 timepoints.
To evaluate specificity, serum samples collected 
before the circulation of SARS-CoV-2 also were test-
ed. This testing was done on residual serum samples 
taken in 2018 and provided by the Sero-Epidemiolo-
gy Unit (SEU) at PHE, Manchester (5), and the Royal 
College of General Practitioners Research and Sur-
veillance Centre (6). All samples were processed and 
stored at the SEU.
Serologic Assays
We tested samples on 2 commercial assays accord-
ing to the manufacturers’ instructions. Initial testing 
was conducted by using the SARS-CoV-2 ELISA IgG 
assay from Euroimmun (https://www.euroimmun.
com) targeting the S1 domain, including the receptor-
binding domain (RBD); testing was conducted by 
using the SARS-CoV-2 IgG for use on the Architect 
platform (Abbott, https://www.molecular.abbott) 
targeting the nucleoprotein. Samples were tested in-
dividually and reported according to the manufac-
turers’ criteria. We defined Euroimmun results of 0.8 
to <1.1 as equivocal and >1.1 as reactive. We defined 
Abbott results of >1.4 as reactive; we also defined an 
equivocal range of 0.8 to <1.4 for presentation of vali-
dation data.
The third assay was an in-house assay devel-
oped in the Virus Reference Department at PHE, 
also used retrospectively. For this ELISA, we pur-
chased the commercial recombinant RBD subunit of 
the SARS-CoV-2 spike protein from SinoBiological 
Inc. (https://www.sinobiological.com), which we 
expressed in HEK293 cell culture with a C-terminal 
mouse Fc tag (Arg319-Phe541(V367F) (GenBank ac-
cession no. YP_009724390.1). We coated Nunc Maxi-
Sorp (Nunc, https://www.thermofisher.com) flat-
bottomed, polystyrene, 96-well microtiter plates by 
diluting 20 ng recombinant protein per well in sterile 
phosphate-buffered saline; pH 7.2 + SD 0.05 (Gibco, 
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https://www.thermofisher.com) at 4°C–8°C for a 
minimum of 16 hours. We diluted serum at a final 
dilution factor of 1 in 100. We detected the binding 
of IgG on the plate surface by using an anti-human 
IgG horseradish peroxidase antibody conjugate (Sig-
ma-Aldrich, https://www.sigmaaldrich.com) and 
3,3′,5,5′-etramethylbenzidine (Europa Bioproducts 
Ltd, https://www.europa-bioproducts.com). We 
analyzed samples in duplicate and evaluated optical 
density at 450 nm (OD450) data by dividing average 
OD450 values for individual samples by average OD450 
of a known calibrator with negative antibody levels 
(T/N ratio). We defined results of 4 to <5 as equivocal 
and >5 as reactive. We defined samples as reactive for 
each assay independently.
Assay Validation
Because of the speed with which the assays have been 
developed, limited validation has been conducted 
by the manufacturers. We therefore used panels cre-
ated by PHE and managed by the SEU to validate the 
assays (7,8)
Population Data
We weighted overall prevalence estimates for age. 
We based these estimates on population data from 
the Office for National Statistics (9).
Statistical Analysis
We calculated observed prevalence (prevobs) by age 
group, sex, and time with 95% exact CIs. In these calcu-
lations, all results falling into the equivocal range of the 
assays were included as negative. Analyses were con-
ducted in Stata 14 (StataCorp, https://www.stata.com).
We corrected observed prevalence to account for 
the sensitivity and specificity of the assays by using 
an adjusted prevalence (prevadj) related to the ob-
served prevalence as follows:
Prevobs = Se × prevadj + (1 – Sp) × (1 – prevadj),
where Se denotes sensitivity, Sp denotes specificity, 
and prevobs denotes the observed prevalence (10,11). 
We solved this relationship within a Bayesian mod-
el, along with the sampling distribution for reactive 
tests n+≈binomial(N, prevobs) and using a beta(0.5,0.5) 
prior for the adjusted prevalence prevadj. We included 
sensitivity and specificity, which were based on posi-
tivity in convalescent and baseline serum samples, 
in our Bayesian model each by way of a conjugate 
beta-binomial model with a beta(0.5,0.5) prior, thus 
accounting for uncertainty of their actual value. We 
generated uncertainty and credible intervals by using 
Markov Chain Monte Carlo simulations with 500,000 
iterations after a burn-in of 1,000 iterations and a thin-
ning interval of 5, using the NIMBLE package in R 
software (12,13).
Results
The overall test positivity based on the Euroimmun 
assay was 2.9% (95% CI 1.8%–4.4%) in week 13, 9.9% 
(95% CI 8.2%–11.8%) in weeks 15–16, and 13.0% (95% 
CI 11.0%–15.3%) in week 18. Consecutive differences 
between the proportion reactive at the 3 timepoints 
reduced over time, from 7.0% (95% CI 4.8%–9.1%) 
during week 13 to weeks 15–16 to 3.2% (95% CI 
0.4%–5.9%) during weeks 15–16 to week 18 (Figure 
1; Appendix Table 1, https://wwwnc.cdc.gov/EID/
article/27/7/20-3167-App1.pdf).
In comparison, results from the RBD and Ab-
bott assays had higher positivity at week 13, RBD at 
3.5% (95% CI 1.9%–5.9%) and Abbot at 3.0% (95% CI 
1.4%–5.6%), compared with a positivity of 2.9% with 
the Euroimmun assay (Figure 1; Appendix Table 1). 
The number of samples tested using each assay var-
ied considerably for this first timepoint. At week 18 
the RBD test had highest positivity at 14.1% (95% 
12.0%–16.5%) and Abbott the lowest at 12.3% (95% CI 
10.3%–14.6%) (Figure 1; Appendix Table 1), although 
the differences in positivity estimated by the 3 assays 
were not significantly different at each of the 3 peri-
ods, producing overlapping CIs. We tested a smaller 
number of donor samples from week 13 using the Ab-
bott assay. The geographic spread of these samples 
was a little more concentrated in inner London com-
pared with the overall sample collection (Appendix 
Table 2) but reasonably representative in terms of age 
(Appendix Table 3).
After adjustment for sensitivity and specificity, 
Euroimmun had the highest adjusted prevalence in 
week 18 at 14.9%, compared with 13.3% for the Ab-
bott assay and 13.4% for the RBD assay (Appendix 
Table 1). In weeks 15–16, adjusted prevalence was 
similar among the 3 assays: 10.9% for RBD, 11.0% for 
Euroimmun, and 11.3% for the Abbott assay. In week 
13, adjusted prevalence was lowest for RBD at 1.5% 
and highest for the Abbott at 3.1%.
Venn diagrams show the results for samples test-
ed by all assays for the 3 timepoints (Figure 2). Unad-
justed prevalence based on a highly specific endpoint 
requiring all assays to be reactive was 1.0%, 8.5% 
and 11.6% at the 3 timepoints, whereas if based on a 
highly sensitive endpoint of any assay reactive prev-
alence was 6.5%, 13.6%, and 14.8%. The RBD assay 
gave the most reactive results, but this tendency can 
be explained by its lower specificity (Appendix, Ap-
pendix Table 5). If a criterion of reactive by Abbott or 
RESEARCH
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Euroimmun were used (to maintain good specificity 
and increase sensitivity), then unadjusted prevalence 
would be 4.5%, 12.2%, and 13.6% for the 3 timepoints. 
These values compare with an unadjusted prevalence 
of 2.9%, 9.9%, and 13.0% for the Euroimmun assay 
alone. To adjust prevalence based on assay combina-
tions, the sensitivity and specificity of these combina-
tions is also required, but the validation data did not 
have all assays tested on the same negative samples 
to enable this calculation.
The analysis shows an important age effect, a 
decreasing prevalence with increasing age group at 
weeks 15–16 (Figure 3; Appendix Table 3), based on 
the Euroimmun assay. Comparisons by age were not 
interpretable for the earlier timepoint (week 13) be-
cause of the low number of donor samples from per-
sons in older age groups. At week 18, the difference 
in prevalence by age group was less pronounced, 
showing little difference between age groups <50 
years and an increased prevalence in older age 
groups. When comparing age effects by assay, this 
effect was most pronounced in the RBD assay results 
and least pronounced in the Abbott assay results 
(Appendix Table 3).
Although prevalence estimates from all 3 assays 
indicate a slightly higher prevalence among men than 
women in week 13 (Appendix Table 6), a more pro-
nounced gender effect appears to have occurred by 
weeks 15–16, when prevalence was higher in younger 
women than in men and older women. This differ-
ence was no longer observed by week 18, when prev-
alence was similar.
Discussion
We demonstrate the value of using 3 serologic as-
says targeting different proteins for evaluating se-
roprevalence of SARS-CoV-2 and for understand-
ing the evolution of the epidemic in London and the 
effects of physical distancing measures. Our results 
show that overall trends in prevalence estimates are 
similar across all 3 assays; however, we observed 
some notable differences. The sensitivity analysis 
indicates that the assay targeting the nucleopro-
tein identifies early infections; the assays targeting 
the spike protein are more reliable in picking up 
late infections. These results are similar to observa-
tions made by other groups (14). Including samples 
that were positive on the nucleoprotein-based as-
say with those reactive on a spike-based assay in-
creased unadjusted prevalence by 1.6%, 2.3%, and 
0.6% for the 3 periods.
Understanding the changes in sensitivity of sero-
logic assays over time is also critical in interpreting 
seroprevalence data, particularly taking into account 
recent data that have indicated differential waning 
patterns for antibodies that have different targets (14). 
These findings also demonstrate the value in combin-
ing data from different serologic assays with different 
target proteins for determining seroprevalence.
We show that, in London, ≈14% donors had evi-











region of England. This pattern is consistent with data 
from other surveillance systems, including numbers 
of cases, hospitalizations, and deaths (15). These re-
sults also confirm transmission slowed substantially 
after lockdown measures were put in place, plateau-
ing from weeks 15–16 to 18. Given the time required 
to develop an antibody response and the fact that do-
nors are excluded from donating for a minimum of 14 
days after an acute illness, these prevalence estimates 
reflect the situation >2–4 weeks before the collection 
date. Therefore, increases observed from weeks 13 to 
15–16 reflect the situation before the effects of lock-
down measures fully taking effect, and results from 
early May reflect incidence from early to mid-April.
Our analysis shows a very pronounced age dif-
ference among adult age groups, particularly for 
samples taken in weeks 15–16, which probably reflect 
the epidemic dynamics under normal social-mixing 
patterns in a high-transmission situation (16), given 
the fact that these results were too early to have been 
affected by lockdown. Those findings suggest that 
young adults in London were infected earlier in the 
epidemic and older age groups affected later. The 
mixing patterns during lockdown have substantially 
changed, including less frequent contact with per-
sons in the same age groups (i.e., less age-assortative 
mixing); fewer daily contacts overall; and more in-
tergenerational mixing among persons >30 years of 
age, probably reflecting household compositions in 
these age groups (17). These patterns might explain, 
in part, some of the observed differences in trends by 
age group.
For prevalence by sex, data from London sug-
gest that young adult women had a higher risk for 
infection than men of the same age, particularly 
before lockdown measures were implemented. 
However, after lockdown, those differences became 
less pronounced. This finding might support the 
hypothesis that women of childbearing age were ac-
quiring infection before men of a similar age group. 
Evidence to support the idea that children are key 
drivers of transmission is limited (17), and further 
work is needed to address potential explanations for 
such a difference, including higher intensity of expo-
sure to children, higher frequencies of occupational 
caring roles for women compared with men, or both.
The availability of large volumes of donor sam-
ples on a weekly basis provided an attractive and 
valuable source of samples for seroprevalence esti-
mates. However, adult donors are not representative 
of the general population and are likely to be less 
ethnically diverse, of higher socioeconomic status, 
and healthier than the wider population (18,19), all 
of which might lead to an underestimate in popula-
tion prevalence. Although donors >70 years of age 
were excluded from donation, increased pathogenic-
ity of SARS-CoV-2 with age might have resulted in an 
increased proportion of infected older donors being 
hospitalized and thus not available for blood dona-
tion. This tendency could result in an underestimate 
of seroprevalence in the oldest age groups.
Changes in the precise locations of sampling 
within regions at different periods have been ob-
served, and this lack of consistent sampling needs 
to be considered when interpreting any changes 
over time. For example, because of limited volumes, 
a smaller number of donor samples from week 13 
were tested using the Abbott assay. We demonstrate 
similar results for using 3 different assays indepen-






and specificity of the assays. We did not attempt 
to estimate adjusted prevalence on a combination 
of assays results or on the basis of changing assays 
cutoffs because more validation data on using mul-
tiple assays would be needed, and those data would 
probably indicate a pattern similar to that observed 
with the individual assays.
A range of interactions might have contributed 
to our results; further work is needed to understand 
the effect of age on antibody kinetics and the effect 
of age on different aspects of various assays, includ-
ing sensitivity over time. These factors highlight the 
complexity inherent in interpreting seroprevalence 
surveys.
Despite those limitations, these results from test-
ing blood donors have provided valuable intelligence 
regarding the progression of the epidemic among 
adults in London. Our results show that using mul-
tiple serologic assays targeting different proteins is 
probably informative as we try to determine the in-
terplay between antibody kinetics and transmission 
dynamics in the population over time. Seroepidemio-
logic studies that rely on a single assay or have a sin-
gle target risk incomplete ascertainment of the actual 
number of infections within the population.
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Dr. Danielle Greenberg, founder of a veterinary clinic 
near Liverpool, knew something was wrong. Dogs in 
her clinic were vomi� ng—and much more than usual. 
Concerned, she phoned Dr. Alan Radford and his team 
at the University of Liverpool for help.
Before long they knew they had an outbreak on their hands. 
In this EID podcast, Dr. Alan Radford, a professor of veterinary 
health informa� cs at the University of Liverpool, recounts the 
discovery of an outbreak of canine enteric coronavirus.
EID Podcast: 
Tracking Canine Enteric Coronavirus in the UK 
Visit our website to listen: h� ps://go.usa.gov/xsMcP 
